Kest B, Mogil J S, Sternberg W F, Pechnick R N, Liebeskind J C
Department of Psychiatry and Biobehavioral Sciences, Neuropsychiatric Institute, UCLA 90024, USA.
Pharmacol Biochem Behav. 1995 Sep;52(1):175-8. doi: 10.1016/0091-3057(95)00085-b.
The role of the sigma receptor in prolonged pain was examined by assessing the effects of 1,3,di-o-tolylguanidine (DTG), a selective sigma receptor ligand, on the formalin test in mice. Formalin injected subcutaneously into the hindpaw produces a biphasic pain response: an acute phase of short duration followed by a longer-lasting tonic phase. DTG (10 mg/kg, i.p.) potently reduced pain behavior in the acute phase but increased pain behavior in the tonic phase. Rimcazole (5 and 10 mg/kg, i.p.), a selective sigma receptor antagonist, blocked both the DTG-induced decrease and increase in pain behavior observed in the acute and tonic phases, respectively. These data support previous findings indicating a modulatory role for the sigma receptor in nociceptive processes, and suggest that this receptor differentially modulates acute vs. tonic pain.
通过评估选择性σ受体配体1,3 - 二邻甲苯基胍（DTG）对小鼠福尔马林试验的影响，研究了σ受体在持续性疼痛中的作用。皮下注射到后爪的福尔马林会产生双相疼痛反应：持续时间较短的急性期，随后是持续时间更长的强直期。DTG（10毫克/千克，腹腔注射）在急性期能有效减轻疼痛行为，但在强直期会增加疼痛行为。选择性σ受体拮抗剂利咪唑（5和10毫克/千克，腹腔注射）分别阻断了在急性期和强直期观察到的DTG诱导的疼痛行为的减少和增加。这些数据支持了先前的研究结果，表明σ受体在伤害感受过程中具有调节作用，并表明该受体对急性疼痛和强直疼痛有不同的调节作用。
